Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program.

BACKGROUND: Common polymorphisms of the transcription factor 7-like 2 gene (TCF7L2) have recently been associated with type 2 diabetes. We examined whether the two most strongly associated variants (rs12255372 and rs7903146) predict the progression to diabetes in persons with impaired glucose tolerance who were enrolled in the Diabetes Prevention Program, in which lifestyle intervention or treatment with metformin was compared with placebo. METHODS: We genotyped these variants in 3548 participants and performed Cox regression analysis using genotype, intervention, and their interactions as predictors. We assessed the effect of genotype on measures of insulin secretion and insulin sensitivity at baseline and at one year. RESULTS: Over an average period of three years, participants with the risk-conferring TT genotype at rs7903146 were more likely to have progression from impaired glucose tolerance to diabetes than were CC homozygotes (hazard ratio, 1.55; 95 percent confidence interval, 1.20 to 2.01; P<0.001). The effect of genotype was stronger in the placebo group (hazard ratio, 1.81; 95 percent confidence interval, 1.21 to 2.70; P=0.004) than in the metformin and lifestyle-intervention groups (hazard ratios, 1.62 and 1.15, respectively; P for the interaction between genotype and intervention not significant). The TT genotype was associated with decreased insulin secretion but not increased insulin resistance at baseline. Similar results were obtained for rs12255372. CONCLUSIONS: Common variants in TCF7L2 seem to be associated with an increased risk of diabetes among persons with impaired glucose tolerance. The risk-conferring genotypes in TCF7L2 are associated with impaired beta-cell function but not with insulin resistance. (ClinicalTrials.gov number, NCT00004992. [ClinicalTrials.gov]).

Pubmed ID: 16855264 RIS Download

Mesh terms: Cohort Studies | Diabetes Mellitus, Type 2 | Disease Progression | Enteroendocrine Cells | Female | Gene Frequency | Genotype | Glucose Metabolism Disorders | Humans | Incidence | Insulin | Insulin Resistance | Linkage Disequilibrium | Male | Middle Aged | Polymorphism, Single Nucleotide | Proportional Hazards Models | Randomized Controlled Trials as Topic | TCF Transcription Factors | Transcription Factor 7-Like 2 Protein

Research resources used in this publication

None found

Research tools detected in this publication

None found

Data used in this publication

None found

Associated grants

  • Agency: NIDDK NIH HHS, Id: R01 DK072041
  • Agency: Intramural NIH HHS, Id: K23 DK65978-03
  • Agency: NIDDK NIH HHS, Id: R01DK072041-01
  • Agency: NIDDK NIH HHS, Id: U01 DK048489
  • Agency: NIDDK NIH HHS, Id: K23 DK065978
  • Agency: NIDDK NIH HHS, Id:

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

We have not found any resources mentioned in this publication.